Jinyu Bio-Technology (600201.SH): Currently, the domestic meat product market has not fully recovered, and the prices of meat, eggs, and milk are at a low point.

On March 20, Gelonghui reported that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the domestic meat product market consumption has not fully recovered yet, with the prices of meat, eggs, and milk at a low point, and downstream customers are still under pressure regarding cash flow, resulting in overall pressure on the Animal Protection Industry. The company leverages its solid R&D foundation and years of experience in the industry, forming differentiated competition through product iteration at the R&D level to succeed in a fiercely competitive market environment.

Gelonghui FinanceMar 20 16:37

Jinyu Bio-Technology (600201.SH): A total of 3.2858 million shares of the company have been repurchased.

On March 3, Gelonghui reported that Jinyu Bio-Technology (600201.SH) announced that, as of February 28, 2025, the company had repurchased 3.2858 million shares through the centralized bidding system of the Shanghai Exchange, accounting for 0.2933% of the company's total share capital, with the highest transaction price being 6.54 yuan/share, the lowest transaction price being 6.37 yuan/share, and the total amount paid being 21.1236 million yuan (excluding commission, transfer fees, and other transaction costs).

Gelonghui FinanceMar 3 17:17

Express News | Jinyu Bio-Technology: Subsidiary Jinyu Baoling has obtained the new veterinary drug registration certificate for bovine mycoplasma live vaccine.

BreakingsFeb 27 16:53

Jinyu Bio-technology Announces New Veterinary Drug Registration

MT NewswiresFeb 19 18:19

Jinyu Bio-Technology (600201.SH): Exploring the application of deepseek in the field of Biological Vaccine research and development.

Gelonghui reported on February 18 that Jinyu Bio-Technology (600201.SH) stated on the interactive platform that the company is currently collaborating with top Universities and research institutes in China, extensively using AI in vaccine development for tasks such as antigen screening and sequence optimization. In the future, AI will continue to be deeply utilized for target selection, process optimization, vaccine design, high-dimensional evaluation, and exploring the application of deepseek in the field of Biological Vaccine research and development.

Gelonghui FinanceFeb 18 18:40

Jinyu Bio-Technology (600201.SH): The Brucella gene deletion live vaccine (RM6 strain, rough type) has obtained a new veterinary drug registration certificate.

Jinyu bio-technology (600201.SH) issued an announcement, according to the national "Regulations on Veterinary Drugs" and "Veterinary Drug Registration Measures" ...

Zhitong FinanceFeb 17 17:02